CVA Family Office’s Chemours CC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$103 Buy
+5
New +$114 ﹤0.01% 1783
2025
Q1
Sell
-26
Closed -$439 1406
2024
Q4
$439 Buy
+26
New +$506 ﹤0.01% 1261
2024
Q3
Sell
-50
Closed -$1.13K 1285
2024
Q2
$1.13K Hold
50
﹤0.01% 1055
2024
Q1
$1.31K Hold
50
﹤0.01% 974
2023
Q4
$1.58K Buy
+50
New +$1.36K ﹤0.01% 930
2023
Q3
Sell
-50
Closed -$1.84K 342
2023
Q2
$1.84K Hold
50
﹤0.01% 893
2023
Q1
$1.5K Hold
50
﹤0.01% 872
2022
Q4
$1.53K Sell
50
-325
-87% -$9.75K ﹤0.01% 841
2022
Q3
$9K Buy
375
+65
+21% +$2.14K ﹤0.01% 638
2022
Q2
$10K Buy
310
+260
+520% +$9.56K ﹤0.01% 635
2022
Q1
$2K Sell
50
-135
-73% -$4.22K ﹤0.01% 864
2021
Q4
$6K Buy
+185
New +$5.76K ﹤0.01% 713
2021
Q3
Sell
-50
Closed -$2K 441
2021
Q2
$2K Hold
50
﹤0.01% 871
2021
Q1
$1K Buy
+50
New +$1.33K ﹤0.01% 744

Other funds holding CC

CVA Family Office's CC Position: Q2 2026 in Review

CVA Family Office opened a new position in Chemours (CC) in Q2 2026: 5 shares worth $103. The stake represents ﹤0.01% of the portfolio and ranks #1783 among its holdings. This is a return to the name: CVA Family Office previously reported a position in CC as recently as Q4 2024.

CVA Family Office first reported a position in CC in Q1 2021 and has held it in 14 quarters since. The position peaked at $10K in Q2 2022. 473 funds tracked by Wall St. Rank hold CC as of Q2 2026.

  • CVA Family Office held 5 shares of Chemours worth $103 as of Q2 2026.
  • Chemours was a new CVA Family Office position in Q2 2026.
  • Chemours made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1783 holding.
  • CVA Family Office first reported a position in Chemours in Q1 2021 and has held it in 14 quarters since.
  • CVA Family Office's Chemours position peaked at $10K in Q2 2022.
  • 473 funds tracked by Wall St. Rank held Chemours as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.